Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultraspeed Resolution Reveals that Ubiquitins Bind Sequentially

By LabMedica International staff writers
Posted on 15 Dec 2009
An innovative reaction quenching protocol with millisecond resolution has revealed that cells attach ubiquitin chains to proteins marked for destruction link by link rather than all at once. More...


The addition of a chain of four or more ubiquitin molecules to a target protein marks that protein for destruction by protein-degrading complexes in the cell. Heretofore, it was not known whether these molecules were added to the target protein sequentially or as a pre-formed chain.

In the current study, investigators at California Institute of Technology (Pasadena, USA) developed new methodology to study the action of ubiquitin ligase, the enzyme complex that attaches ubiquitin to the target protein at short time intervals that had not previously been possible. For this purpose, they adapted an instrument called a "quench-flow" machine, a machine that allows for extreme precision in the stopping, or "quenching," of a reaction. This instrument allowed them to follow changes in structure at intervals as short as 10 milliseconds in both yeast and human proteins.

"We devised methods to take snapshots of ubiquitin ligase reactions at a rate of up to 100 "pictures" every second," said senior author Dr. Raymond Deshaies, professor of biology at the California Institute of Technology. "This enables us to see things that would normally evade detection. Prior methods did not have sufficient time resolution to see what was going on. It is as if you gave an ice-cream cone to a kid and took pictures every minute. You would see the ice cream disappear from the first photo to the next, but since the pictures are too far apart in time, you would have no idea whether the child ate the ice cream one bite at a time, or swallowed the entire scoop in one gulp."

Results published in the December 3, 2009, issue of the journal Nature revealed that the three ubiquitin ligase enzymes, E1, E2, and E3 work as a team to build polyubiquitin chains on substrates by sequential transfers of single ubiquitins.

"The new method revealed the biological equivalent of small, single bites of ice cream," said Dr. Deshaies. "Using our approach we could see that our ubiquitin ligase builds ubiquitin chains one ubiquitin at a time. Gaining these kinds of insights into the ubiquitin system is important because ubiquitin ligases play a critical role in a number of human diseases, including cancer, due to their role in the regulation of the cell cycle."

Related Links:
California Institute of Technology



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.